Table 3

Predictive value of PROMIS self-efficacy on HRQoL in patients from the Almenara Lupus Cohort

PCSMCS
Univariable modelMultivariable modelUnivariable modelMultivariable model
B (SE)P valueB (SE)p valueB (SE)P valueB (SE)p value
Self-efficacy for managing daily activities1.59 (0.13)<0.0010.22 (0.13)0.0911.44 (0.13)<0.0010.39 (0.13)0.002
Self-efficacy for managing symptoms1.26 (0.14)<0.0010.25 (0.11)0.0211.19 (0.13)<0.0010.32 (0.12)0.006
Self-efficacy for managing medications and treatment*0.71 (0.17)<0.0010.20 (0.10)0.0460.65 (0.16)<0.0010.24 (0.10)0.016
Self-efficacy for managing emotions0.99 (0.16)<0.0010.12 (0.11)0.2571.05 (0.15)<0.0010.17 (0.11)0.161
Self-efficacy for managing social interactions0.77 (0.15)<0.0010.27 (0.09)0.0020.86 (0.14)<0.0010.37 (0.10)<0.001
General self-efficacy0.98 (0.11)<0.0010.18 (0.08)0.0370.92 (0.11)<0.0010.20 (0.10)0.051
  • Adjusted for age at diagnosis, gender, socioeconomic status, SLEDAI-2K, SLICC/American College of Rheumatology Damage Index, disease duration at baseline, prednisone daily dose, antimalarial and immunosuppressive drugs use and the PCS or MCS in the previous visit.

  • Values in bold are those that are statistically significant.

  • *One patient was excluded as she was not taking any medication during her follow-up.

  • HRQoL, health-related quality of life; MCS, mental component summary; PCS, physical component summary; PROMIS, Patient-Reported Outcomes Measurement Information System; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2K; SLICC, Systemic Lupus International Collaborating Clinics.